Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Magstim receives US approval for Rapid2 Therapy System

Magstim receives US approval for Rapid2 Therapy System

20th May 2015

Magstim has announced that its Rapid2 Therapy System has been approved for the treatment of drug-resistant major depressive disorder in the US.

The US Food and Drug Administration has ratified the cutting-edge repetitive transcranial magnetic stimulation technology based on the benefits it can provide to patients who have failed to respond to traditional pharmaceutical medication.

People with depression commonly display reduced blood flow in the left dorsolateral prefrontal cortex (DLPFC) and heightened activity in the limbic system, thus affecting their ability to regulate mood.

Magstim's system works by stimulating the DLPFC directly via a completely non-invasive technique that can be performed as an outpatient procedure.

Robin Davies, chief executive officer of Magstim, said the approval "means that we can offer quality solutions and improved choice for both the clinician and patient".

Based in Wales, Magstim creates medical devices for use in neuroscience research labs and clinical psychiatry centres. It was founded in 1990 and has won the Queen's Award for International Trade.ADNFCR-8000103-ID-801788207-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.